. Author manuscript; available in PMC: 2024 Jul 1.

Published in final edited form as: Pharmacotherapy. 2023 Jun 22;43(7):650–658. doi: 10.1002/phar.2836

Table 1:

Demographics of the study participants.

Participant # by Site	54 (24%) Seattle Children’s Hospital 105 (46%) Texas Children’s Hospital 69 (30%) Boston Children’s Hospital
Sex	94 (41%) Female 134 (59%) Male
Race	159 (70%) White 28 (12%) Black 41 (18%) Unknown/Other
Ethnicity	161 (71%) Non-Hispanic 65 (29%) Hispanic 2 (<1%) Unknown/Other
Age (yr)	10.7 (3.7, 15.3)
Weight (kg)	30.9 (14.3, 52.8)
Creatinine Clearance (mL/min/1.73m², Bedside Schwartz)	116 (82.1, 125)
ALT (IU/L)	32.0 (24, 46)
AST (IU/L)	37.0 (29, 74)
Hemoglobin (g/dL)	11.8 (11.0, 12.7)
Hematocrit (%)	35.7 (34.5, 36.7)
Tacrolimus Trough Concentration (ng/mL)	9.00 (6.60, 11.5)
Total Daily Dose (mg)	2.8 (1.2, 5.0)

Continuous variables are reported as median (interquartile range)